Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFRONT-3 Phase 3 study of latozinemab in GRN mutation-associated frontotemporal dementia
2023-506873-36-00Phase 3Completed
- Sponsor
- Alector
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3 trial of latozinemab, sponsored by Alector. Started Oct 2024; status: completed.
02
Drugs
latozinemab
Beyond the preview
Go deeper on 2023-506873-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506873-36-00.